Hemogenyx Pharmaceuticals plc

In light of the measures currently in place in the United Kingdom in response to the COVID-19 pandemic and in order to protect the health and safety of the Company's Shareholders and Directors, the Directors have taken the decision to use the flexibility provided for in the Corporate Governance and Insolvency Act 2020 to hold the General Meeting as a virtual meeting on 6 January 2021 at 2:00 p.m. (London time). Shareholders are strongly encouraged to appoint "the Chair of the meeting" as their proxy. If any other person is appointed as proxy, he or she will be able to attend, submit written questions and vote at the General Meeting remotely via the Lumi virtual meeting platform, further details of which are set out in the circular containing the Notice of General Meeting. The completion and return of this Form of Proxy (by post or email) (or transmission of a proxy appointment through CREST or by any other procedure described in the Notice of General Meeting) will not prevent you from remotely attending, submitting written questions and voting at the General Meeting, in each case via the Lumi virtual meeting platform, if you are entitled to and wish to do so.

Shareholder Reference Number

PIN number

Please detach this portion before posting this proxy form.

Form of Proxy - General Meeting to be held on 6 January 2021

To be effective, all proxy appointments must be lodged with the Company's Registrars at: Computershare Investor Services PLC,
The Pavilions, Bridgwater Road, Bristol BS99 6ZY by 4 January 2021 at 2:00 pm (GMT).

Explanatory Notes:

- 1. Every holder has the right to appoint some other person(s) of their choice, who need not be a shareholder, as his proxy to exercise all or any of his rights, to attend, speak and vote on their behalf at the meeting. You are strongly encouraged to appoint the Chairman as your proxy. If any other person is appointed as proxy, he will not be able to attend the General Meeting in person, but will be able to attend, submit written questions and vote at the General Meeting remotely via the Lumi virtual meeting platform. If returned without an indication as to how the proxy shall vote on any particular matter, the proxy will exercise his discretion as to whether, and if so how, he votes (or if this proxy form has been issued in respect of a designated account for a shareholder, the proxy will exercise his discretion as to whether, and if so how, he votes).
- 2. The 'Vote Withheld' option overleaf is provided to enable you to abstain on any particular resolution. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
- 3. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, entitlement to attend and vote at the meeting and the number of votes which may be cast thereat will be determined by reference to the Register of Members of the Company at 6:00 p.m. (London time) on the day which is two business days before the date of the meeting. Changes to entries on the Register of Members after that time shall be disregarded in determining the rights of any person to attend and vote at the meeting.
- 4. To appoint one or more proxies or to give an instruction to a proxy (whether previously appointed or otherwise) via the CREST system, CREST messages must be received by the issuer's agent (ID number 3RA50) not later than 48 hours before the time appointed for holding the meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp generated by the CREST system) from which the issuer's agent is able to retrieve the message. The Company may treat as invalid a proxy appointment sent by CREST in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
- 5. The above is how your address appears on the Register of Members. If this information is incorrect please ring the Registrar's helpline on 0330 303 1185 to request a change of address form or go to www.investorcentre.co.uk to use the online Investor Centre service.
- 6. Any alterations made to this form should be initialled.
- 7. The completion and return of this form will not preclude a member from attending the meeting and voting via the Lumi virtual meeting platform.

Kindly Note: This form is issued only to the addressee(s) and is specific to the unique designated account printed hereon. This personalised form is not transferable between different: (i) account holders; or (ii) uniquely designated accounts. The Company and Computershare Investor Services PLC accept no liability for any instruction that does not comply with these conditions.

All Named Holders								

In light of the measures currently in place in the United Kingdom in response to the COVID-19 pandemic and in order to protect the health and safety of the Company's Shareholders and Directors, the Directors have taken the decision to use the flexibility provided for in the Corporate Governance and Insolvency Act 2020 to hold the General Meeting as a virtual meeting on 6 January 2021 at 2:00 p.m. (London time). Shareholders are strongly encouraged to appoint "the Chair of the meeting" as their proxy. If any other person is appointed as proxy, he or she will be able to attend, submit written questions and vote at the General Meeting remotely via the Lumi virtual meeting platform, further details of which are set out in the circular containing the Notice of General Meeting. The completion and return of this Form of Proxy (by post or email) (or transmission of a proxy appointment through CREST or by any other procedure described in the Notice of General Meeting) will not prevent you from remotely attending, submitting written questions and voting at the General Meeting, in each case via the Lumi virtual meeting platform, if you are entitled to and wish to do so.

Ple	Orm of Proxy ase complete this box only if you wish to appoint a third party proxy oth blank if you want to select the Chairman. Do not insert your own name							
		*				7		
en	We hereby appoint the Chairman of the Meeting OR t httlement* on my/our behalf at the General Meeting of January 2021 at 2:00 pm (London time) and at any	of Hemogenyx Pharmaceuticals Pl						
* *	For the appointment of more than one proxy, please refer to	Explanatory Note 4 (see front).		Diagon upo o bi	ack non Mor	k with on V		
	Please mark here to indicate that this proxy appo	pintment is one of multiple appoir	ntments being made.	Please use a bl inside the box a		is example.		
Or	rdinary Resolutions			For	Against	Vote Withheld		
	THAT, for the purposes of Article 94.2 of the Articles, the undertakings for the time being (the "Group") and remain hereby are permitted to exceed an amount equal to two respect of the issue of up to £60,000,000 in principal arthereby authorised to issue the Convertible Loan Notes an Article 94 of the Articles.	ning outstanding at any time (excluding times the Adjusted Capital and Reser mount of Convertible Loan Notes and	ng intra-Group borrowings) be and ves (as defined in the Articles) in that the Directors be and they are					
2.	THAT, subject to and conditional on the passing of Resolution 1, in accordance with section 551 of the Companies Act 2006 (the "Act"), and in addition to all existing and unexercised authorities (and without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such existing or unexercised authorities), the Directors be and they are hereby generally and unconditionally authorised to exercise all powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of £60,000,000 in connection with the issue of the Convertible Loan Notes, provided that this authority will expire on the fifth anniversary of the date on which this resolution is passed unless any such authorities are renewed, varied or revoked by the Company prior to or on that date and provided that the Company may, before such expiry, make an offer or agreement which would or might require shares in the Company or rights to be allotted or granted after such expiry and that the Directors may allot shares in the Company or grant rights pursuant to such an offer or agreement as if the authority conferred by this Resolution 2 had not expired.							
Sr	pecial Resolution							
	THAT, subject to and conditional upon the passing of Resolutions 1 and 2, in accordance with section 571(1) of the Act, the Directors be and are hereby empowered, in addition to all existing and unexercised authorities, to allot equity securities for cash (within the meaning of section 560 of the Act) pursuant to the authority conferred by Resolution 2 above, as if section 561 of the Act did not apply to any such allotment, provided that this power shall: (i) be limited to the allotment of equity securities up to an aggregate nominal value of £60,000,000 in connection with the issue of the Convertible Loan Notes; and (ii) expire on the fifth anniversary of the date on which this resolution is passed, but may be previously revoked or varied by special resolution and so that the Company may, before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if such power had not expired.							
I/V	Ve instruct my/our proxy as indicated on this form. Unles	s otherwise instructed the proxy ma	y vote as he or she sees fit or abst	ain in relation to	any business	of the meeting.		
Si	ignature	Date						
		DD/MM/YY	seal or be signed on its be	In the case of a corporation, this proxy must be given under its common seal or be signed on its behalf by an attorney or officer duly authorised, stating their capacity (e.g. director, secretary).				
		WKF0567	0 7	SVE				